Venetoclax
Acute Leukemia of Ambiguous Lineage
National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
55/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 73/ 100
Competitive context
45 Active assets in the Acute Leukemia of Ambiguous Lineage cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide SWOG Cancer Research Network | Phase 2 | BB |
L-Ofloxacin Children's Oncology Group | Phase 3 | BB |
METHOTREXATE SWOG Cancer Research Network | Phase 2 | B |
Cytosin-Arabinosid SWOG Cancer Research Network | Phase 2 | B |
VINCRISTINE SULFATE Children's Oncology Group | Phase 2 | B |
View all 50 →
Same molecule, other indications
Venetoclax is also rated in:
Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveDormant
BBB
Indicative ·
72 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →